Clinical Trials

Find a Trial

Trial Results

41 protocol(s) meet the specified criteria
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
A061402OPEN TO ACCRUAL
SOLITARY PLASMACYTOMA OF BONE: RANDOMIZED PHASE III TRIAL TO EVALUATE TREATMENT WITH ADJUVANT SYSTEMIC TREATMENT AND ZOLEDRONIC ACID VERSUS ZOLEDRONIC ACID AFTER DEFINITE RADIATION THERAPY
A221405/IBCSG48-POSITIVEOPEN TO ACCRUAL
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy(POSITIVE)
BBI608-201OPEN TO ACCRUAL
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
BR-076OPEN TO ACCRUAL
A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 ( pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
BRE12-158OPEN TO ACCRUAL
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
BTCRC-GI13-002OPEN TO ACCRUAL
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
C16011OPEN TO ACCRUAL
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
CP-MGAH22-04OPEN TO ACCRUAL
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
E1Z11OPEN TO ACCRUAL
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E2112OPEN TO ACCRUAL
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
EAY131-C1/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
EAY131-C2/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
EAY131-L/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
EAY131-M/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
EAY131-Z1C/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
EAY131-Z1E/MATCHOPEN TO ACCRUAL
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
EAY131/MATCHOPEN TO ACCRUAL
Molecular Analysis for Therapy Choice (MATCH)
GOG-0238OPEN TO ACCRUAL
A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUCRO-0216OPEN TO ACCRUAL
Indiana University Simon Cancer Center Hematologic Malignancies Tissue Bank
IUCRO-0373OPEN TO ACCRUAL
A Path Analysis Modeling of the Interaction of AXII and/or AXIIR with the Changes in Cytokines and Myeloma Bone Disease (The Cytokine Protocol)
IUCRO-0498OPEN TO ACCRUAL
Role of Osteocytes in Myeloma Bone Disease
IUSCC-0555OPEN TO ACCRUAL
Inhibiting fatty acid synthase to improve efficacy of neoadjuvant chemotherapy.
IUSCC-0590OPEN TO ACCRUAL
iMETX (Individualized Metabolic RX): a pilot study of an environmental intervention to increase energy expenditure among breast cancer survivors
IUSCC-0612OPEN TO ACCRUAL
Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults with Metastatic Cancer and Their Family Caregivers
IUSCC-0613OPEN TO ACCRUAL
An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
LCCC1317OPEN TO ACCRUAL
Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab
NEOD001-OLE251OPEN TO ACCRUAL
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
NSABP-B-55/BIG6-13OPEN TO ACCRUAL
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
NSMM-5001OPEN TO ACCRUAL
A Global, prospective, non-interventional, observation study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
PHO-COG-FALLON-AHEP0731OPEN TO ACCRUAL
Treatment of Children with All Stages of Hepatoblastoma
PRE0109OPEN TO ACCRUAL
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer [AFT-05]
RTOG-0848OPEN TO ACCRUAL
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PHIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
S1416OPEN TO ACCRUAL
PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
TBCRC035OPEN TO ACCRUAL
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers
TBCRC037OPEN TO ACCRUAL
A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer
TBCRC040OPEN TO ACCRUAL
Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer